Published in Cardiovasc Res on March 01, 2003
Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res (2008) 1.80
Angiotensin II-induced upregulation of AT(1) receptor expression: sequential activation of NF-kappaB and Elk-1 in neurons. Am J Physiol Cell Physiol (2010) 1.13
AP-1 and colorectal cancer. Inflammopharmacology (2005) 1.07
Earliest changes in the left ventricular transcriptome postmyocardial infarction. Mamm Genome (2006) 1.03
Regulation of heat shock protein 60 and 72 expression in the failing heart. J Mol Cell Cardiol (2009) 1.01
Regulation of cardiac excitation and contraction by p21 activated kinase-1. Prog Biophys Mol Biol (2009) 0.99
Repression of miR-142 by p300 and MAPK is required for survival signalling via gp130 during adaptive hypertrophy. EMBO Mol Med (2012) 0.99
Innate immunity and remodelling. Heart Fail Rev (2011) 0.98
The NF-κB subunit c-Rel stimulates cardiac hypertrophy and fibrosis. Am J Pathol (2011) 0.98
Nuclear GPCRs in cardiomyocytes: an insider's view of β-adrenergic receptor signaling. Am J Physiol Heart Circ Physiol (2011) 0.97
AFos dissociates cardiac myocyte hypertrophy and expression of the pathological gene program. Circulation (2005) 0.97
Use of cell permeable NBD peptides for suppression of inflammation. Ann Rheum Dis (2006) 0.94
A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFkappaB activity. Mol Cancer (2009) 0.93
Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice. J Physiol (2011) 0.91
Functional polymorphism of the NFKB1 gene promoter is related to the risk of dilated cardiomyopathy. BMC Med Genet (2009) 0.90
Therapeutic targeting of innate immunity in the failing heart. J Mol Cell Cardiol (2010) 0.89
Citrate synthase is a novel in vivo matrix metalloproteinase-9 substrate that regulates mitochondrial function in the postmyocardial infarction left ventricle. Antioxid Redox Signal (2014) 0.88
Dynamic reorganization of the AC16 cardiomyocyte transcriptome in response to TNFα signaling revealed by integrated genomic analyses. BMC Genomics (2014) 0.84
Molecular determinants of the cardiometabolic phenotype. Endocr Metab Immune Disord Drug Targets (2010) 0.84
MicroRNA involvement in immune activation during heart failure. Cardiovasc Drugs Ther (2011) 0.84
The function of miRNA in cardiac hypertrophy. Cell Mol Life Sci (2012) 0.82
Selective impairment of nuclear factor-kappaB-dependent gene transcription in adult cardiomyocytes: relevance for the regulation of the inflammatory response in the heart. Am J Pathol (2007) 0.82
AFos inhibits phenylephrine-mediated contractile dysfunction by altering phospholamban phosphorylation. Am J Physiol Heart Circ Physiol (2010) 0.81
Gene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failure. Genome Med (2015) 0.80
In vivo transfection of manganese superoxide dismutase gene or nuclear factor κB shRNA in nodose ganglia improves aortic baroreceptor function in heart failure rats. Hypertension (2013) 0.79
The pathological roles of environmental and redox stresses in cardiovascular diseases. Environ Health Prev Med (2012) 0.78
Efficacy of female rat models in translational cardiovascular aging research. J Aging Res (2014) 0.77
The use of moderate hypothermia during cardiac surgery is associated with repression of tumour necrosis factor-alpha via inhibition of activating protein-1: an experimental study. Crit Care (2006) 0.77
Angiotensin II-superoxide-NFκB signaling and aortic baroreceptor dysfunction in chronic heart failure. Front Neurosci (2015) 0.77
Genetically altered mutant mouse models of guanylyl cyclase/natriuretic peptide receptor-A exhibit the cardiac expression of proinflammatory mediators in a gene-dose-dependent manner. Endocrinology (2014) 0.77
Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II. Cardiovasc Res (2015) 0.77
Recombinant adeno-associated virus serotype 9 with p65 ribozyme protects H9c2 cells from oxidative stress through inhibiting NF-κB signaling pathway. J Geriatr Cardiol (2014) 0.75
Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a. Exp Ther Med (2016) 0.75
A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. Sci Rep (2017) 0.75
Understanding chronic heart failure. Arch Dis Child (2007) 0.75
Regulation of cardiac angiotensin-converting enzyme and angiotensin AT1 receptor gene expression in Npr1 gene-disrupted mice. Clin Exp Pharmacol Physiol (2009) 0.75
Murine Electrophysiological Models of Cardiac Arrhythmogenesis. Physiol Rev (2017) 0.75
Knockout of the ATPase inhibitory factor 1 protects the heart from pressure overload-induced cardiac hypertrophy. Sci Rep (2017) 0.75
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension (2012) 6.70
MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation (2007) 6.41
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res (2008) 3.30
Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation (2009) 2.88
Airway obstruction in systolic heart failure--COPD or congestion? Int J Cardiol (2013) 2.73
Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int (2009) 2.72
Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol (2011) 2.54
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation (2003) 2.22
Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation (2008) 2.18
Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation (2012) 2.14
Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes (2007) 2.12
Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation (2009) 2.07
Incidence rates and predictors of major and minor depression in patients with heart failure. Int J Cardiol (2012) 2.05
International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail (2015) 2.03
Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol (2005) 1.99
MicroRNA-24 regulates vascularity after myocardial infarction. Circulation (2011) 1.98
Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ Res (2010) 1.96
Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol (2011) 1.94
The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun (2012) 1.88
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol (2005) 1.83
Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med (2007) 1.83
Susceptibility-sensitive magnetic resonance imaging detects human myocardium supplied by a stenotic coronary artery without a contrast agent. J Am Coll Cardiol (2003) 1.81
Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res (2008) 1.80
Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest (2004) 1.77
Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension (2007) 1.68
The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc Res (2005) 1.66
Bone marrow molecular alterations after myocardial infarction: Impact on endothelial progenitor cells. Cardiovasc Res (2006) 1.65
Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res (2007) 1.61
Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation (2006) 1.60
Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension (2011) 1.59
Atheroprotective effects of neuronal nitric oxide synthase in apolipoprotein e knockout mice. Arterioscler Thromb Vasc Biol (2006) 1.58
Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging (2013) 1.54
Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis. Am J Cardiol (2011) 1.53
Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol (2003) 1.52
Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol (2008) 1.52
Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail (2014) 1.52
Supramolecular nanostructures that mimic VEGF as a strategy for ischemic tissue repair. Proc Natl Acad Sci U S A (2011) 1.50
Transgenic myocardial overexpression of prokineticin receptor-2 (GPR73b) induces hypertrophy and capillary vessel leakage. Cardiovasc Res (2008) 1.50
Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction. J Mol Cell Cardiol (2002) 1.50
Aging reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female spontaneously hypertensive rats. Hypertension (2006) 1.49
Assessment of the contractile reserve in patients with intermediate coronary lesions: a strain rate imaging study validated by invasive myocardial fractional flow reserve. Eur Heart J (2007) 1.47
Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J (2003) 1.46
The different faces of echocardiographic left ventricular hypertrophy: clues to the etiology. J Am Soc Echocardiogr (2010) 1.45
Echocardiographic quantification of regional deformation helps to distinguish isolated left ventricular non-compaction from dilated cardiomyopathy. Eur J Heart Fail (2012) 1.45
Tei index in fabry disease. J Am Soc Echocardiogr (2011) 1.44
The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol (2005) 1.43
Role of endothelial nitric oxide synthase in endothelial activation: insights from eNOS knockout endothelial cells. Am J Physiol Cell Physiol (2004) 1.43
Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis. J Am Coll Cardiol (2008) 1.43
Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol (2003) 1.43
Absence of NF-kappaB subunit p50 improves heart failure after myocardial infarction. FASEB J (2006) 1.42
Fractalkine promotes platelet activation and vascular dysfunction in congestive heart failure. Thromb Haemost (2013) 1.41
99mTc-HMPAO-labeled autologous versus heterologous leukocytes for imaging infection. J Nucl Med (2002) 1.41
How to successfully implement E-learning for both students and teachers. Acad Radiol (2006) 1.41
ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost (2008) 1.40
Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation (2007) 1.37
Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. Circ Heart Fail (2009) 1.35
Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and ischemic stress. Circulation (2006) 1.33
The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J (2005) 1.32
Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur J Nucl Med Mol Imaging (2002) 1.31
Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J (2012) 1.31
Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med (2005) 1.28
Dysnatraemia in heart failure. Eur J Heart Fail (2012) 1.28
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis (2007) 1.24